Factors Affecting Survival in Breast Cancer Patients following Bone Metastasis

Yavas, Ozlem; Hayran, Mutlu; Özışık, Yavuz

doi:10.1177/030089160709300611

Cited by 24 publications

(24 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our data, these primary sites constitute 74.6% cases out of a total of 114 cases with known primary. A slight difference in the pattern of metastatic bone disease which we found was that lung, thyroid and kidney cancer implants in bone are less common and secondary bone involvement by ovarian and gastrointestinal cancers is more common as compared to international data available (Berruti et al, 2000;Yavas et al, 2007).…”

Section: Discussioncontrasting

confidence: 66%

Metastatic Bone Disease as Seen in Our Clinical Practice - Experience at a Tertiary Care Cancer Center in Pakistan

Qureshi

Shams

Akhter

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussioncontrasting

confidence: 66%

Metastatic Bone Disease as Seen in Our Clinical Practice - Experience at a Tertiary Care Cancer Center in Pakistan

Qureshi

Shams

Akhter

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Recently, a retrospective observational study showed that the median overall survival after diagnosis of prostate cancer with spinal metastases was 24 months with an estimated 1-year overall survival of 73 % [9]. The median survival time after diagnosis of breast cancer with bone metastases was 32 months [10].…”

Section: Prognosismentioning

confidence: 99%

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

Jia

2014

Clin Transl Oncol

View full text Add to dashboard Cite

Several cancers tend to metastasize to bone, leading to osteolytic or osteoblastic bone lesions. The respective phenotypes of bone destruction and bone formation vary in clinical features, including incidence, prognosis, skeletal-related events and bone biomarkers. In addition, different molecular mechanisms explain the difference in phenotype. For example, molecules involved in osteolytic bone metastases (represented with breast cancer) include parathyroid hormone-related protein, transforming growth factor-β, while in osteoblastic lesions (represented with prostate cancer), endothelin-1 and morphogenetic proteins, etc. play a more important role in bone formation. It is important for us to understand the differences of bone metastases between two phenotypes to help clinicians to understand the underlying mechanisms, behaviors and therapies in development and currently available for bone metastases.

show abstract

“…Among women with bone metastases from breast cancer, median survival is approximately 2 to 3 years (8), in comparison with the 12-to 18-month median survival in patients with liver metastases (9). Unfortunately, specific prognostic models for long-term survival in patients with bone metastases from breast cancer are not well developed (10)(11)(12)(13)(14). We have previously shown that elevated baseline levels of the biochemical marker N-telopeptide of type I collagen (NTX) were associated with an increased risk of SREs (15,16), and normalization of NTX levels correlated with reduced risks of fracture, SREs, and death versus persistently elevated NTX after 3 months of treatment with zoledronic acid (ZOL; refs.…”

Section: Introductionmentioning

confidence: 99%

Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients

Brown

Cook

Lipton

et al. 2012

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Survival is highly variable in women with bone metastases from breast cancer and prognostic factors are needed. We analyzed data from a phase III trial comparing zoledronic acid (ZOL) with pamidronate in patients with breast cancer and bone metastases to identify variables prognostic for overall survival.Experimental Design: Patients who received ZOL (n ¼ 435) with bone marker assessments and complete baseline data were included. Relative risks (RR) of death over 24 months were assessed using a stratified Cox regression analysis. A reduced model was generated using stepwise backward elimination until only significant (P < 0.05) variables remained.Results: Only 5 of 19 variables analyzed remained significantly prognostic for survival in the reduced multivariate model. These included age more than 50 years (RR 1.78-2.53, P 0.01 for each decade >50 versus 50); Functional Assessment of Cancer Therapy-General (FACT-G) score less than 65 units (P < 0.05 vs. !75 units); impaired (PS ! 1) versus fully active (PS ¼ 0) Eastern Cooperative Oncology Group (ECOG) performance status (RR 1.74, P < 0.01); prior versus no prior chemotherapy (RR 1.97; P < 0.01), and lactate dehydrogenase (LDH) levels. Lactate dehydrogenase ! upper limit of normal (ULN) but < 2 Â ULN correlated with a two-fold increased risk of death, and LDH > 2 Â ULN correlated with a six-fold increased risk of death versus LDH < ULN (P < 0.0001 for both). Baseline bone marker levels were not significantly correlated with survival after adjustment for other significant covariates.Conclusions: This retrospective analysis shows that LDH levels correlate strongly with survival in patients with bone metastases from breast cancer and confirms the relevance of previously described prognostic factors.

show abstract

Factors Affecting Survival in Breast Cancer Patients following Bone Metastasis

Abstract: In the result of study, for patients with breast cancer, survival following bone metastasis is affected by secondary prognostic factors such as disease-free interval and extent of metastasis besides primary prognostic factors related to the primary tumor.

Cited by 24 publications

References 18 publications

Metastatic Bone Disease as Seen in Our Clinical Practice - Experience at a Tertiary Care Cancer Center in Pakistan

Metastatic Bone Disease as Seen in Our Clinical Practice - Experience at a Tertiary Care Cancer Center in Pakistan

Differences of osteoblastic bone metastases and osteolytic bone metastases in clinical features and molecular characteristics

Serum Lactate Dehydrogenase Is Prognostic for Survival in Patients with Bone Metastases from Breast Cancer: A Retrospective Analysis in Bisphosphonate-Treated Patients

Contact Info

Product

Resources

About